

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: McAllister, *et al.* 23 April 2010  
Serial No.: 10/598,810 Group Art Unit: 1615  
Filed: 11 March 2005 Examiner: Sheikh, H.  
For: PHARMACEUTICAL FORMULATIONS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. Applicants submit herewith an updated listing of their copending applications as shown on page 1 of the accompanying 1449 form, along with additional citations shown on page 2 of the 1449 form. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

  
/ Dara L. Dinner /  
Dara L. Dinner  
Attorney for Applicants  
Registration No. 33,680

GLAXOSMITHKLINE  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5017  
Facsimile (610) 270-5090